Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer
Our findings support the implementation of DPYD genotyping prior to capecitabine initiation in metastatic breast cancer patients. This strategy exemplifies the value of personalized medicine and pharmacogenomics in improving treatment safety and effectiveness. As sequencing technologies advance and become affordable, integration of genotyping into routine oncology care is increasingly feasible.
Authors
- Anne Hudson Blaes (ORCID: https://orcid.org/0000-0002-5433-4810)
- Tanvi Chiddarwar
- KM Kuntz
Institutions
- University of Minnesota (US)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2026-03-28
- DOI
- https://doi.org/10.1007/s10549-026-07948-y
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.00